Jan 3, 2016 · Aducanumab dose-dependently reduced amyloid deposition in six cortical regions of the brain. The effect was large: After one year, the highest dose appeared to have reduced …

Oct 22, 2024 · Previously, Lars Lannfelt at Uppsala University, Sweden, who started the development of lecanemab, had reported that the antibody bound Aβ protofibrils more strongly …

Sep 12, 2016 · The enthusiasm for aducanumab should rest on its PK, PD, plaque-busting ability, preclinical biochemical characteristics, and clinical safety. One doesn’t need to invoke …

Feb 6, 2024 · Biogen has thrown in the towel on its controversial anti-amyloid antibody aducanumab. The company announced January 31 that it would stop all development of the …

Sep 28, 2020 · The authors report data on mouse versions of four clinical antibodies, namely aducanumab, bapineuzumab, solanezumab and gantenerumab. The side-by-side comparison …

For example, Ken Marek at the Institute for Neurodegenerative Disorders in New Haven, Connecticut, believes the aducanumab decision heralds the beginning of a new era in …

Nov 20, 2021 · For aducanumab, cost and absent insurance coverage mean fewer patients than expected are on it so far. In a new blow to aducanumab’s prospects, the European Medicines …

Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD. The effectiveness and value of aducanumab for Alzheimer's disease. J Manag Care Spec Pharm. 2021 Nov;27 (11):1613 …

Nov 20, 2020 · Because aducanumab has to be infused, expense and logistics are also considerations. “We presently are woefully unprepared to incorporate any truly effective …

Nov 11, 2023 · Trontinemab rapidly clears plaque with little ARIA. Potentially, this is because its direct brain delivery method sidesteps vascular amyloid. Breaching the blood-brain barrier via …